Date: 2014-12-22
Type of information: Licensing agreement
Compound:
Company: EpiVax (USA - RI) Novozymes (Denmark)
Therapeutic area:
Type agreement: licensing development
Action mechanism:
Disease: autoimmune diseases
Details: * On December 22, 2014, EpiVax and Novozymes Biopharma announced that they have entered a license agreement for the development of novel treatments for autoimmune diseases. The agreement follows two years of successful feasibility studies and it allows EpiVax to use Novozymes\' albumin technologies to develop cutting edge immunotherapies. EpiVax has identified a set of natural peptide sequences, called Tregitopes, derived from Immunoglobulin G that are potent activators of natural T regulatory cells (hence Tregitope). The initial application targeted by the Novozymes/EpiVax collaboration will be the development of a recombinant alternative to intravenous IgG (IVIG) treatment, a global market that exceeded $6 billion in 2014. Tregitopes will be fused to albumin, a naturally occurring protein that can be found in human blood. Albumin works as a vehicle that transports the therapy throughout the body and increases the lifespan of the therapy. The albumin is produced by Novozymes and known as VELTIS®.
Financial terms:
Latest news:
